|
US9829494B2
(en)
|
2005-12-01 |
2017-11-28 |
Adrenomed Ag |
Methods of treatment using ADM antibodies
|
|
EP3252079B8
(en)
|
2006-04-07 |
2020-09-09 |
Aerpio Therapeutics LLC |
Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
|
|
TWI510246B
(zh)
*
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制vegf-a受體交互作用的經修飾結合性蛋白質
|
|
AU2014243418B2
(en)
*
|
2010-04-30 |
2016-09-22 |
Molecular Partners Ag |
Modified binding proteins inhibiting the VEGF-A receptor interaction
|
|
EP2643349B1
(en)
|
2010-11-26 |
2019-09-04 |
Molecular Partners AG |
Designed repeat proteins binding to serum albumin
|
|
KR20140039203A
(ko)
|
2011-04-29 |
2014-04-01 |
얀센 바이오테크 인코포레이티드 |
Il4/il13 결합 반복 단백질 및 용도
|
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
|
CN104039351A
(zh)
|
2011-10-13 |
2014-09-10 |
阿尔皮奥治疗学股份有限公司 |
用于治疗血管渗漏综合征和癌症的方法
|
|
PL2594587T3
(pl)
|
2011-11-16 |
2014-11-28 |
Adrenomed Ag |
Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry
|
|
HRP20170427T1
(hr)
|
2011-11-16 |
2017-06-16 |
Sphingotec Gmbh |
Testovi na adrenomedulin i postupci određivanja zrelog adrenomedulina
|
|
SG10201802054TA
(en)
|
2011-11-16 |
2018-05-30 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
|
|
NZ624873A
(en)
|
2011-11-16 |
2016-07-29 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
|
|
KR102249078B1
(ko)
|
2011-11-16 |
2021-05-10 |
아드레노메드 아게 |
요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
|
|
ES2751492T3
(es)
|
2011-11-16 |
2020-03-31 |
Adrenomed Ag |
Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o armazón no Ig anti-ADM para uso en la terapia de una enfermedad aguda o una afección aguda de un paciente para estabilizar la circulación
|
|
CN103308670B
(zh)
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
|
CN103308673B
(zh)
|
2012-03-08 |
2017-05-31 |
思芬构技术有限公司 |
用于预测雌性对象中发生心血管事件的风险的方法
|
|
CN103308689B
(zh)
|
2012-03-08 |
2017-04-12 |
思芬构技术有限公司 |
用于预测雌性对象中患上癌症的风险或诊断癌症的方法
|
|
WO2013169614A1
(en)
*
|
2012-05-07 |
2013-11-14 |
Allergan, Inc. |
Method of treating amd in patients refractory to anti-vegf therapy
|
|
EA033161B1
(ru)
|
2012-06-01 |
2019-09-30 |
Новартис Аг |
Шприц
|
|
WO2014001442A1
(en)
*
|
2012-06-28 |
2014-01-03 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to platelet-derived growth factor
|
|
AU2012101677B4
(en)
|
2012-07-03 |
2012-12-20 |
Novartis Ag |
Device
|
|
AU2013100071C4
(en)
*
|
2012-07-03 |
2013-05-02 |
Novartis Ag |
Device
|
|
DE202013000688U1
(de)
|
2012-07-03 |
2013-03-05 |
Novartis Ag |
Glas-Spritze
|
|
JP2015528454A
(ja)
*
|
2012-08-28 |
2015-09-28 |
ノバルティス アーゲー |
眼血管増殖性疾患の処置におけるvegfアンタゴニストの使用
|
|
DK2904403T3
(en)
|
2012-10-02 |
2018-07-16 |
Sphingotec Gmbh |
PROCEDURE FOR DIAGNOSTICATION OR MONITORING OF Kidney Function or Diagnosis of Kidney Function
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
RU2677895C2
(ru)
|
2013-01-08 |
2019-01-22 |
Сфинготек Гмбх |
Уровни гормона роста натощак в качестве прогностического маркера сердечно-сосудистого риска
|
|
CN110845618A
(zh)
*
|
2013-02-26 |
2020-02-28 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
JP6649246B2
(ja)
*
|
2013-03-14 |
2020-02-19 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法
|
|
SG10201800309SA
(en)
|
2013-03-20 |
2018-02-27 |
Sphingotec Gmbh |
Adrenomedullin to guide therapy of blood pressure decline
|
|
FR3004650B1
(fr)
*
|
2013-04-22 |
2015-05-29 |
Affilogic |
Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
|
|
US11453708B2
(en)
|
2013-05-31 |
2022-09-27 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to hepatocyte growth factor
|
|
WO2014203181A1
(en)
|
2013-06-20 |
2014-12-24 |
Novartis Ag |
Treatment of polypoidal choroidal vasculopathy
|
|
EP3010526A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating macular edema
|
|
EP3010525A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating choroidal neovascularisation
|
|
US20160168240A1
(en)
|
2013-07-11 |
2016-06-16 |
Sergey AKSENOV |
Use of vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
RU2676303C2
(ru)
*
|
2013-07-11 |
2018-12-27 |
Новартис Аг |
Использование антагониста vegf для лечения ретролентальной фиброплазии
|
|
EA201690212A8
(ru)
|
2013-07-12 |
2016-08-31 |
Офтотек Корпорейшн |
Способы лечения или профилактики офтальмологических патологических состояний
|
|
EP3628324A1
(en)
*
|
2013-11-05 |
2020-04-01 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
|
EP3828202A1
(en)
|
2014-05-12 |
2021-06-02 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
|
EP3002589A1
(en)
|
2014-10-01 |
2016-04-06 |
sphingotec GmbH |
A method for stratifying a female subject for hormone replacement therapy
|
|
US9458211B1
(en)
|
2015-04-02 |
2016-10-04 |
Molecular Partners Ag |
Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
|
|
WO2016170023A1
(en)
|
2015-04-24 |
2016-10-27 |
Sphingotec Gmbh |
A method for predicting the risk of incidence of chronic kidney disease
|
|
TWI799366B
(zh)
*
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
|
RU2751510C2
(ru)
|
2015-11-18 |
2021-07-14 |
Сио2 Медикал Продактс, Инк. |
Фармацевтическая упаковка для офтальмологических составов
|
|
WO2018218013A2
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
US20180326126A1
(en)
|
2015-11-18 |
2018-11-15 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
CN108883172A
(zh)
|
2015-11-18 |
2018-11-23 |
福迈康股份公司 |
包含vegf拮抗剂的液体配制品的预填充药物包装
|
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
CN109073660B
(zh)
|
2016-02-29 |
2022-10-28 |
麦恩泰科特有限公司 |
可用于治疗湿性年龄相关性黄斑变性的预测性标志物
|
|
CH713803B1
(de)
|
2016-04-21 |
2023-08-15 |
4TEEN4 Pharmaceuticals GmbH |
Verfahren zur Diagnose durch Bestimmung von DPP3, Hemmer der Aktivität von DPP3 und Zusammensetzung mit einem Hemmer.
|
|
EP3474887A1
(en)
|
2016-06-27 |
2019-05-01 |
AiCuris Anti-infective Cures GmbH |
Hcmv entry inhibitors
|
|
JP7191813B2
(ja)
|
2016-07-08 |
2022-12-19 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
急性心不全に罹患している対象におけるうっ血を評価するためのアドレノメデュリン
|
|
WO2018017714A1
(en)
|
2016-07-20 |
2018-01-25 |
Aerpio Therapeutics, Inc. |
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
|
|
AR109680A1
(es)
|
2016-09-22 |
2019-01-09 |
Molecular Partners Ag |
Proteínas recombinantes y sus usos
|
|
EP3309550A1
(en)
|
2016-10-12 |
2018-04-18 |
sphingotec GmbH |
Method for the detection of apolipoprotein e4
|
|
MX2019007107A
(es)
|
2016-12-16 |
2019-10-21 |
Adrenomed Ag |
Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
|
|
EP3339324A1
(en)
|
2016-12-22 |
2018-06-27 |
sphingotec GmbH |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
BR112019024966A2
(pt)
|
2017-05-30 |
2020-06-23 |
Sphingotec Gmbh |
Método para diagnosticar ou monitorar a função renal ou diagnosticar a disfunção renal
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
CN111225976A
(zh)
*
|
2017-08-18 |
2020-06-02 |
剑桥企业有限公司 |
模块化结合蛋白
|
|
WO2019057992A2
(en)
|
2017-09-25 |
2019-03-28 |
Adrenomed Ag |
ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE
|
|
BR112020005682A2
(pt)
|
2017-10-18 |
2020-10-20 |
Adrenomed Ag |
monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm)
|
|
EP3701266A1
(en)
|
2017-10-24 |
2020-09-02 |
sphingotec GmbH |
Selenoprotein p for prediction of a first cardiovascular event
|
|
MY202502A
(en)
|
2017-10-25 |
2024-05-01 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
|
|
EP3749959A1
(en)
|
2018-02-08 |
2020-12-16 |
sphingotec GmbH |
Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
|
|
EP3569614A1
(en)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
|
|
EP3586865A1
(en)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
|
|
CN120058958A
(zh)
|
2018-09-24 |
2025-05-30 |
视点制药公司 |
靶向HPTP-β(VE-PTP)和VEGF的多特异性抗体
|
|
AU2019408553A1
(en)
|
2018-12-20 |
2021-06-17 |
Sphingotec Gmbh |
Selenoprotein P in heart failure
|
|
WO2020128039A2
(en)
|
2018-12-21 |
2020-06-25 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
|
|
AU2020289080A1
(en)
|
2019-06-04 |
2021-12-23 |
Molecular Partners Ag |
Multispecific proteins
|
|
EP4014049A1
(en)
|
2019-08-15 |
2022-06-22 |
sphingotec GmbH |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
|
|
EP4552649A3
(en)
|
2019-08-30 |
2025-06-25 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for treatment of shock
|
|
CN114929730A
(zh)
|
2019-12-11 |
2022-08-19 |
分子合作伙伴股份公司 |
重组肽-mhc复合物结合蛋白及其生成和用途
|
|
EP3871689A1
(en)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
|
|
WO2021170880A2
(en)
|
2020-02-27 |
2021-09-02 |
Adrenomed Ag |
Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
|
|
AU2021228207A1
(en)
|
2020-02-27 |
2022-10-20 |
4TEEN4 Pharmaceuticals GmbH |
DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock
|
|
CA3168978A1
(en)
|
2020-02-27 |
2021-09-02 |
Andreas Bergmann |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
|
MX2022011583A
(es)
|
2020-03-16 |
2022-10-18 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 en pacientes infectados con coronavirus.
|
|
EP3922993A1
(en)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
EP4121772A1
(en)
|
2020-03-16 |
2023-01-25 |
sphingotec GmbH |
Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
|
|
MX2022013945A
(es)
|
2020-05-06 |
2023-02-14 |
Molecular Partners Ag |
Nuevas proteinas de union a repeticiones de anquirina y sus usos.
|
|
JP2023528204A
(ja)
|
2020-05-14 |
2023-07-04 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
多選択性タンパク質
|
|
EP4023218A1
(en)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Combination therapy for patients having acute and/or persistent dyspnea
|
|
WO2022130300A1
(en)
|
2020-12-16 |
2022-06-23 |
Molecular Partners Ag |
Novel slow-release prodrugs
|
|
JP2024509904A
(ja)
|
2021-03-09 |
2024-03-05 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
新規なDARPinに基づく多重特異性T細胞エンゲージャ
|
|
US20240156980A1
(en)
|
2021-03-09 |
2024-05-16 |
Molecular Partners Ag |
Protease cleavable prodrugs
|
|
AU2022233791A1
(en)
|
2021-03-09 |
2023-09-28 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
|
EP4304730A1
(en)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Novel darpin based cd33 engagers
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
WO2022263648A1
(en)
|
2021-06-18 |
2022-12-22 |
Sphingotec Gmbh |
A method for predicting sepsis and septic shock
|
|
KR20240041912A
(ko)
|
2021-06-29 |
2024-04-01 |
베리솔 게엠베하 |
체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
IL313411A
(en)
|
2021-12-14 |
2024-08-01 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity and their use
|
|
CN119072492A
(zh)
|
2022-03-15 |
2024-12-03 |
艾德里诺医药公司 |
抗肾上腺髓质素(adm)抗体或抗adm抗体片段的稳定水性制剂
|
|
EP4562430A1
(en)
|
2022-07-29 |
2025-06-04 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
|
IL318667A
(en)
|
2022-07-29 |
2025-03-01 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
|
CN119731200A
(zh)
|
2022-08-01 |
2025-03-28 |
分子合作伙伴股份公司 |
经电荷修饰设计的重复结构域及其用途
|
|
WO2024038307A1
(en)
|
2022-08-19 |
2024-02-22 |
Novartis Ag |
Dosing regimens for sars-cov-2 binding molecules
|
|
WO2024059686A2
(en)
*
|
2022-09-15 |
2024-03-21 |
The Regents Of The University Of California |
Darpin backbones and rigidified electron microscopy imaging scaffolds
|
|
JP2025541138A
(ja)
|
2022-12-15 |
2025-12-18 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
重篤な患者における肺機能の改善のためのdpp3阻害剤
|
|
WO2024179981A1
(en)
|
2023-02-27 |
2024-09-06 |
Molecular Partners Ag |
Darpins for use in reducing renal accumulation of drugs
|
|
CN120731367A
(zh)
|
2023-03-17 |
2025-09-30 |
Pam治疗诊断有限公司 |
肽基甘氨酸α-酰胺化单加氧酶(PAM)的测定方法及其诊断用途
|
|
EP4687942A1
(en)
|
2023-03-29 |
2026-02-11 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
|
|
WO2025068313A1
(en)
|
2023-09-25 |
2025-04-03 |
Sphingotec Gmbh |
A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
|
|
WO2025146491A1
(en)
|
2024-01-05 |
2025-07-10 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
|
|
WO2025229075A1
(en)
|
2024-05-03 |
2025-11-06 |
Sphingotec Gmbh |
A method for the specific determination of proenkephalin fragment 119-159
|
|
WO2025248139A1
(en)
|
2024-05-31 |
2025-12-04 |
4TEEN4 Pharmaceuticals GmbH |
Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
|
|
EP4675277A1
(en)
|
2024-07-05 |
2026-01-07 |
Predemtec AG |
A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease
|
|
WO2026046978A1
(en)
|
2024-08-26 |
2026-03-05 |
Pam Theragnostics Gmbh |
Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects
|
|
WO2026046968A1
(en)
|
2024-08-26 |
2026-03-05 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 binders for the treatment of endothelial dysfunction
|